Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Neuroscience Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for EPHB2 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen (WT & Mutant) | EPHB2 ECD-Fc Fusion Protein (WT and mutant variants). High purity (>95%), Endotoxin <1EU/ug. HEK293 Expressed (Native Glycosylation). Sequence Verified. | View EPHB2 Products |
| Gene Delivery | EPHB2 Lentivirus Premade Particles (full-length ORF) and Promise-ORF lentivirus for stable cell line construction. Preserves native conformation. | View EPHB2 Products |
| Benchmark Ab | Anti-EPHB2 (Clinical Lead Sequence). Recombinant positive control for binding assays. | View EPHB2 Products |
| Validator | EPHB2 siRNA Set. For knockdown verification and specificity controls. | View EPHB2 Products |
| EPHB4 (Selectivity) | EPHB4 ECD-Fc Protein. Critical off-target screening (high homology subfamily). | View EPHB4 Products |
| EPHB1 (Homolog) | EPHB1 ECD-Fc Protein. Closely related homolog for stringent cross-reactivity screening. | View EPHB1 Products |
| EPHA2 (Panel) | EPHA2 ECD-Fc Protein. For broad Eph receptor selectivity profiling. | View EPHA2 Products |
| EFNB1 (Ligand) | EFNB1 Recombinant Protein. Native ligand for competitive binding assays. | View EFNB1 Products |
| EFNB2 (Ligand) | EFNB2 Recombinant Protein. Primary endogenous ligand for receptor binding assays. | View EFNB2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| EphB4 vs EphB2 Selectivity (Subfamily cross-reactivity) | Human EphB4 and EphB2 ortholog proteins available with >95% purity; strict mass spec verified for domain integrity |
| Internalization Efficiency (ADC Development) | Full-length EPHB2 Lentivirus for stable cell line generation; enables live-cell imaging and pH-dependent trafficking studies |
| Ligand Competition (Ephrin-B1/B2 blocking) | Native-folded EFNB1/EFNB2 proteins for SPR/BLI competition assays; maintain physiological binding affinity |
| Cross-species Cyno/Mouse Translation | Human, Mouse, and Cyno EPHB2 ECD-Fc proteins with sequence-verified extracellular domains |
| False Positives / Off-target Binding & Lack of Controls | Validated EPHB2 siRNA for specificity verification; clinical benchmark antibodies included for assay standardization |
Live EPHB2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for EPHB2 therapeutics is intensifying, with major players shifting focus from broad-spectrum kinase inhibitors and traditional monoclonal antibodies to targeted biologics, antibody-drug conjugates (ADCs), and bispecifics. As first-generation small molecule inhibitors face selectivity challenges against the highly homologous EphB4 oncogenic driver, the next wave of R&D is targeting differentiation through epitope-specific antibody blockade, ligand-directed delivery systems, and bypassing resistance mechanisms in colorectal and prostate cancers. The tumor microenvironment modulation and overcoming resistance in solid tumors are key areas of current preclinical investigation.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| ADC (Antibody-Drug Conjugate) | Emerging biotech, Academic labs | Colorectal Cancer, Glioblastoma | Internalization Assay (Need high-purity EPHB2 ECD-Fc for binding validation) |
| Bispecific Antibodies | Preclinical developers | Solid Tumors (T-cell engagers) | Cross-reactivity Panel (Need Human/Mouse/Cyno ortholog proteins) |
| Small Molecule Inhibitors | Early discovery programs | Neuropathic Pain, Cancer | Selectivity Assay (Need EPHB4, EPHA2 mutant vs WT proteins) |
| Ligand Traps (Decoys) | Academic research | Axon regeneration, Inflammation | Ligand Competition (Need EFNB1/EFNB2 native proteins) |
Molecular Insights: Key Mutations and Domains
EPHB2 (UniProt P29323) contains key functional domains: an Eph ligand-binding domain (LBD) and two fibronectin type-III repeats (FN3-1 and FN3-2). Clinically relevant mutations have been identified in prostate cancer, including rs201754821 and rs35882952 (both associated with prostate cancer), and rs56180036. These mutations underscore the need for mutant-specific reagents for drug resistance and selectivity studies. TarMart provides both wild-type and mutant EPHB2 ECD-Fc proteins to support such investigations.